Histidine Triad Nucleotide Binding Protein 1 Attenuates Cardiac Hypertrophy via Suppressing Homeobox A5 Expression
Yan Zhang,Qiang Da,Siyi Cao,Ke Yan,Zhiguang Shi,Qing Miao,Chen Li,Lulu Hu,Shixiu Sun,Wei Wu,Lingxiang Wu,Feng Chen,Liansheng Wang,Yuanqing Gao,Zhengrong Huang,Yongfeng Shao,Hongshan Chen,Yongyue Wei,Feng Chen,Yi Han,Liping Xie,Yong Ji,Qing Miu
DOI: https://doi.org/10.1161/circulationaha.120.051094
IF: 37.8
2021-06-10
Circulation
Abstract:Background: Cardiac hypertrophy is an important pre-pathology of heart failure, which will ultimately lead to heart failure. However, the mechanisms underlying pathological cardiac hypertrophy remain largely unknown. The aim of this study is to elucidate the effects and mechanisms of histidine triad nucleotide binding protein 1 (HINT1) in cardiac hypertrophy and heart failure. Methods: HINT1 was down-regulated in human hypertrophic heart samples compared with non-hypertrophic samples by mass spectrometry analysis. Hint1 knockout mice were challenged with TAC (transverse aortic constriction) surgery. Cardiac specific overexpression of HINT1 mice by intravenous injection of adeno-associated viral (AAV9) encoding Hint1 under the cardiac troponin T (cTnT) promoter were subjected to TAC. Unbiased transcriptional analyses were used to identify the downstream targets of HINT1. AAV9 bearing shRNA against Homeobox A5 ( Hoxa5 ) was administrated to investigate whether the effects of HINT1 on cardiac hypertrophy were HOXA5 dependent. RNA-Seq analysis was performed to recapitulate possible changes in transcriptome profile. Co-immunoprecipitation assays and cellular fractionation analyses were conducted to examine the mechanism by which HINT1 regulates the expression of HOXA5. Results: The reduction of HINT1 expression was observed in the hearts from hypertrophic patients and pressure overloaded-induced hypertrophic mice, respectively. In Hint1 deficient mice, cardiac hypertrophy was deteriorated after TAC. Conversely, cardiac specific overexpression of HINT1 alleviated cardiac hypertrophy and dysfunction. Unbiased profiler PCR-array showed Homeobox A5 (HOXA5) is one target for HINT1, and the cardioprotective role of HINT1 was abolished by HOXA5 knockdown in vivo . Hoxa5 was identified to affect hypertrophy through TGF-β signal pathway. Mechanically, HINT1 inhibited PKCβ1 membrane translocation and phosphorylation via direct interaction, attenuating MEK/ERK/YY1 signal pathway, down-regulating HOXA5 expression and eventually attenuating cardiac hypertrophy. Conclusions: HINT1 protects against cardiac hypertrophy through suppressing HOXA5 expression. These findings indicate that HINT1 may be a potential target for therapeutic interventions in cardiac hypertrophy and heart failure.
cardiac & cardiovascular systems,peripheral vascular disease